Alternative outcome definitions and their effect on the performance of methods for observational outcome studies

Drug Safety

Volumn 36, Issue SUPPL.1, 2013, Pages

  Reich, Christian G ^a,d   Ryan, Patrick B ^b,d   Schuemie, Martijn J ^c,d  

^a ASTRAZENECA   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DATA BASE; HUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

ACUTE KIDNEY INJURY; AREA UNDER CURVE; BIAS (EPIDEMIOLOGY); DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY AS TOPIC; RESEARCH DESIGN;

EID: 84892930541     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0111-1     Document Type: Article

References (18)

1. Barron BA. The effects of misclassification on the estimation of relative risk. Biometrics. 1977;33(2):414-8.
2. Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: Rationale and design for the Observational Medical Outcomes Partnership. Ann Int Med. 2010;153(9):600-6.
3. Carnahan RM, Moores KG. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: Methods and lessons learned. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):82-9.
4. Stang PE, Ryan PB, Dusetzina SB, Hartzema AG, Reich C, Overhage JM, et al. Health outcomes of interest in observational data: Issues in identifying definitions in the literature. Health Outcomes Res Med. 2012;3(1):e37-44.
5. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clinical Pract. 2008;109(4):c182-7.
6. James M, Pannu N. Methodological considerations for observational studies of acute kidney injury using existing data sources. J Nephrol. 2009;22(3):295-305.
7. Katz AJ, Ryan PB, Racoosin JA, Stang PE. Assessment of case definitions for identifying acute liver injury in large observational databases. Drug Saf. 2013;36(8):651-61.
8. Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf (in this supplement issue). doi:10.1007/s40264- 013-0108-9.
9. Observational Medical Outcomes Partnership Methods Library; 2012. http://omop.org/HOI [cited 2012 December 13].
10. Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for Evidence Based Epidemiology. Drug Saf (in this supplement issue). doi:10.1007/s40264-013- 0102-2
11. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf (in this supplement issue). doi:10.1007/s40264-013-0097-8
12. Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126(2):356-8.
13. Reich C, Ryan PB, Suchard MA. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system. Drug Saf (in this supplement issue). doi:10.1007/s40264-013-0112-0
14. Cantor SB, Kattan MW. Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making. 2000;20(4):468-70.
15. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977;105(5):488-95.
16. Wacholder S, Armstrong B, Hartge P. Validation studies using an alloyed gold standard. Am J Epidemiol. 1993;137(11):1251-8.
17. Evans JM, MacDonald TM. Misclassification and selection bias in case-control studies using an automated database. Pharmacoepidemiol Drug Saf. 1997;6(5):313-8.
18. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8): 954-9.